Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer Clinical Trial

— SANOVO  

Official title:

A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05009836
• Other study ID #: 2020-504-00CH4
• Status: Recruiting
• Phase: Phase 3
• Start date: September 6, 2021
• Est. completion date: January 31, 2025

Study information

• Verified date: March 2023
• Source: Hutchmed
• Contact: Lu Chen
• Phone: +86 021 -20673000
• Email: Luc[@]hutch-med.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Description:

A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib Combined with Osimertinib versus Placebo Combined with Osimertinib as the First-line Therapy for Patients with EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 320
• Est. completion date: January 31, 2025
• Est. primary completion date: November 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 28 Years and older

Eligibility

Inclusion Criteria:

1. Fully aware of this study and voluntary to sign the informed consent form, and being willing and able to comply with the study procedure;

2. Age = 18

3. In accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, and patients with histologically or cytologically confirmed unresectable locally advanced (stage ?B/?C), metastatic or recurrent (stage IV) NSCLC who are not suitable for radical concurrent chemoradiotherapy;

4. Carrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression

5. Having measurable lesions (in accordance with RECIST 1.1 criteria);

6. ECOG Performance Status score 0 or 1, or Karnofsky score =80;

7. Survival is expected to exceed 12 weeks;

8. No any previous systematic antitumor therapy for advanced/metastatic disease;

9. adequate bone marrow reserve or organ function

10. Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 4 weeks after discontinuation of the study drug 11. Male patients whose sexual partners are women of childbearing potential must use condoms during sexual intercourse during the study and within 6 months after discontinuation of study drug

12. Being able to take or swallow the drug orally.

Exclusion Criteria:

1. Previous treatment with EGFR inhibitors or MET inhibitors;

2. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years

3. Antitumor therapy within 2 weeks prior to the start of study treatment, including hormone therapy, biotherapy, immunotherapy or the traditional Chinese medicine for antitumor indication;

4. Having received extensive radiotherapy (including radionuclide therapy, e.g., Sr-89) within 4 weeks prior to the start of study treatment or palliative local radiotherapy within one week prior to the start of study treatment, or the above adverse reactions of radiotherapy did not recover;

5. Having received a major surgery within 4 weeks prior to the start of study treatment or a minor surgery (except biopsy, and venous catheterization) within one week prior to the start of study treatment;

6. Currently receiving the potent CYP3A4 inducers or potent CYP1A2 inhibitors within two weeks prior to the start of study treatment;

7. Having not been sufficiently recovered from the toxicity and/or complication resulting from any interventional measure prior to the start of treatment;

8. Clinically significant active infection, including but not limited to tuberculosis, human immunodeficiency virus (HIV) infection (positive HIV1/2 antibody);

9. Active hepatitis B, or active hepatitis C;

10. Acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack;

11. Uncontrollable hypertension despite the use of drugs,

12. Mean resting corrected QT interval (QTcF) or Any important abnormality in rhythm;

13. Patients whose known cancerous thrombus or deep vein thrombosis are stable for =2 weeks after receiving treatment with low molecular weight heparin (LMWH) or analogues with similar efficacy can be enrolled;

14. Any important abnormality in rhythm

15. Presence of meningeal metastasis, spinal cord compression or active brain metastasis prior to the start of study treatment.

16. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;

17. Lack of compliance with participation in this clinical study or inability to comply with the limitations and requirements of the study, as judged by investigators;

18. Having participated in other drug clinical trials and received the study drug within 3 weeks prior to the start of study treatment; 19. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib; 20. Previous history of interstitial lung diseases, drug-induced interstitial lung diseases, radiation pneumonitis requiring glucocorticoid therapy and any active interstitial lung diseases; 21. Pregnant and lactating women; 22. Any other disease, metabolic abnormality, physical examination abnormality or laboratory examination abnormality, certain disease or state, based on which there is a reason to suspect that the subject is not suitable for the study drug, or one condition that will affect intepretaton of the study results or put the subject at high risk.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non-small Cell Lung Cancer

Intervention

Drug:
• Savolitinib
Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
• Placebo
Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse

Locations

Country	Name	City	State
China	Guangdong General Hospital	Guangzhou

Sponsors (1)

Lead Sponsor	Collaborator
Hutchison Medipharma Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)	17 months after the last patient enrolled
Secondary	Safety and tolerability	Incidence and nature of treatment emergent adverse events (TEAE), the other safety variables including physical examination, vital signs and laboratory examinations	17 months after the last patient enrolled
Secondary	The objective response rate of the tumor (ORR)	the incidence of confirmed complete response or partial response	17 months after the last patient enrolled
Secondary	The disease control rate (DCR)	the incidence of complete response, partial response and stable disease	17 months after the last patient enrolled
Secondary	Duration of Response (DoR)	the duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded	17 months after the last patient enrolled
Secondary	Overall survival (OS)	the time from the date of randomization to the date of death (all causes)	17 months after the last patient enrolled
Secondary	Time to Response (TTR)	the period from the date of randomization to the date when the criteria for complete response or partial response was first measured (first record shall prevail).	17 months after the last patient enrolled
Secondary	PFS	Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)	17 months after the last patient enrolled
Secondary	Development of diagnostic technology	The residual samples may be used for development of MET Companion Diagnostics (CDx)	17 months after the last patient enrolled